Cost-Effectiveness of Lowering Cholesterol in Older Patients after Heart Attack. Ann Intern Med. 2000;132:780. doi: 10.7326/0003-4819-132-10-200005160-00037
Download citation file:
Published: Ann Intern Med. 2000;132(10):780.
Statins are drugs used to lower cholesterol levels. Use of statin therapy to lower cholesterol levels in patients younger than 75 years of age who have had a previous heart attack (secondary prevention) is well accepted in the medical community. However, the use of statins in patients older than 75 years of age has not been well studied. Thus, little is known about the costs and benefits of secondary prevention with statins for patients in this age group.
To find out the relative costs and benefits of secondary prevention with statin drugs in patients older than 75 years of age.
Using actual patients to answer this question would require studying many patients, with many different combinations of risk factors, over many years. Instead, the researchers used computers to simulate what would happen to a “virtual” group of 75- to 84-year-old patients who had had a past heart attack.
The authors used information from studies of actual patients 65 to 75 years of age to estimate how statin treatment might affect the occurrence of heart attacks, strokes, and death in patients 75 to 84 years of age. They used a computer model to estimate how much treatment with a statin drug would cost for each additional quality-adjusted life-year (QALY) gained by treatment. These QALYs take into account how well a person is during the time that they are alive. Because actual information on patients in this age group is not available, the researchers studied the effect of varying the potential costs and benefits of statin treatment over a wide range.
In patients 75 to 84 years of who had had a previous heart attack, statin therapy to lower cholesterol levels was estimated to cost approximately $18,800 per QALY saved. In 75% of the cases that the researchers created by varying the costs and benefits of treatment in their computer model, statin treatment cost less than $40,000 per QALY.
This study was a computer simulation. We cannot be sure what the results would be with actual patients. The ratio of costs to benefits for statin treatment might be unfavorable if the drugs were substantially more expensive or substantially less effective at lowering cholesterol levels and decreasing the risk for heart attack, stroke, and death than the researchers estimated.
For people older than 75 years of age who have had a previous heart attack, the benefit of secondary prevention with statin drugs relative to the costs of using these drugs appears to compare favorably with the ratio of benefits to costs for other commonly used health interventions.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Cardiology, Emergency Medicine, Geriatric Medicine, Healthcare Delivery and Policy, Acute Coronary Syndromes.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only